ACE2 and cancer: Of the 13 compounds that showed blocking by binding to either ACE2 or Spike RBD, 2 did not progress further, dactinomycin, a highly toxic chemotherapeutic for a wide range of cancers (31), and zotarolimus, a nonsoluble stent protective agent (32).